Wide Ranks

BBIO

BridgeBio Pharma, Inc.

27.49

Top Statistics
Market Cap 5 B Forward PE -7.53 Revenue Growth -33.20 %
Current Ratio 3.19 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -201.53 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -13.08 Enterprise / Revenue 30.63 Price To Sales Trailing12 Months 23.86
Profitability
Profit Margins -201.53 % Operating Margins -6849.52 %
Balance Sheet
Total Cash 266 M Total Cash Per Share 1.41 Total Debt 1 B
Total Debt To Equity Current Ratio 3.19 Book Value Per Share -6.51
All Measures
Short Ratio 1085.00 % Message Board Id finmb_412911458 Shares Short Prior Month 17 M
City Palo Alto Uuid d3adccf0-6693-305c-9651-8da79033d61c Previous Close 26.44
First Trade Date Epoch Utc 1 B Book Value -6.51 Beta 1.09
Total Debt 1 B Volume 2 M Fifty Two Week Low 21.62
Total Cash Per Share 1.41 Total Revenue 217 M Shares Short Previous Month Date 1 B
Target Median Price 47.50 Audit Risk 2 Max Age 86400
Recommendation Mean 1.61 Sand P52 Week Change 0.3133 Operating Margins -6849.52 %
Target Mean Price 48.52 Net Income To Common -438860000 Short Percent Of Float 0.1396
Implied Shares Outstanding 188 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 3 M Average Volume10days 3 M Total Cash 266 M
Next Fiscal Year End 1 B Revenue Per Share 1.19 Held Percent Insiders 0.0540
Ebitda Margins -234.15 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 9 Regular Market Previous Close 26.44
Target Low Price 36.40 Gmt Off Set Milliseconds -18000000 Fifty Day Average 25.00
Open 26.48 Free Cashflow -365117120 State CA
Dividend Yield 0.00 % Return On Assets -0.4888 Time Zone Short Name EST
Board Risk 9 Trailing Eps -2.42 Day Low 26.25
Address1 3160 Porter Drive Shares Outstanding 188 M Compensation Risk 7
Price Hint 2 Target High Price 70.00 Website https://bridgebio.com
52 Week Change -0.0425 Average Volume 2 M Forward Eps -3.06
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 193.20 %
Is_sp_500 False Regular Market Day High 28.20 Profit Margins -201.53 %
Fifty Two Week High 44.32 Day High 28.20 Shares Short 17 M
Regular Market Open 26.48 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 30.63 Revenue Growth -33.20 % Shares Percent Shares Out 0.0909
Operating Cashflow -450219008 Currency USD Time Zone Full Name America/New_York
Market Cap 5 B Is_nasdaq_100 False Zip 94304
Quote Type EQUITY Industry Biotechnology Long Name BridgeBio Pharma, Inc.
Overall Risk 8 Regular Market Day Low 26.25 Held Percent Institutions 0.9445
Current Price 27.49 Address2 Suite 250 Enterprise To Ebitda -13.08
Financial Currency USD Current Ratio 3.19 Gross Margins 98.90 %
Industry Disp Biotechnology Number Of Analyst Opinions 16 Country United States
Float Shares 128 M Two Hundred Day Average 27.15 Governance Epoch Date 1 B
Enterprise Value 6 B Price To Sales Trailing12 Months 23.86 Forward PE -7.53
Regular Market Volume 2 M Ebitda -509903008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.

BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.